Publicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (114)

2024

  1. An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial

    The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810

  2. CTNND1 is involved in germline predisposition to early-onset gastric cancer by affecting cell-to-cell interactions

    Gastric Cancer, Vol. 27, Núm. 4, pp. 747-759

  3. Colonoscopy Satisfaction and Safety Questionnaire based on patient experience (CSSQP): A valuable quality tool for all colonoscopies

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 1-13

  4. Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 10, pp. 2062-2074.e11

  5. Development and validation of a faecal immunochemical test-based model in the work-up of patients with iron deficiency anaemia

    Frontiers in Medicine, Vol. 11

  6. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

  7. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  8. HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study of the ENEIDA registry.

    American Journal of Gastroenterology

  9. Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588

  10. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  11. Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 12, pp. 1604-1615

  12. Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.

    Digestive and Liver Disease

  13. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  14. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

    Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853

  15. Predictive factors for decompensating events in patients with cirrhosis with primary biliary cholangitis under different lines of therapy

    Hepatology (Baltimore, Md.), Vol. 80, Núm. 4, pp. 791-806

  16. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

    Digestive and Liver Disease, Vol. 56, Núm. 12, pp. 2060-2068

  17. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

  18. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  19. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

  20. Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU

    Digestive and Liver Disease